A review of the methods used to estimate the cost of Alzheimer's disease in the United States

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 4, 2011, Pages 298-309

  Mauskopf, Josephine ^a   Mucha, Lisa ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b PFIZER INC   (United States)

Author keywords

Alzheimer's disease; disease severity; systematic review; US costs

Indexed keywords

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER; COGNITION; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; PATIENT CARE; REVIEW; SYSTEMATIC REVIEW (TOPIC); UNITED STATES;

EID: 79960482061     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317511407481     Document Type: Review

References (46)

1. Zhu CW, Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging. 2006 ; 1 (2). 143-154.
2. Hope T., Keene J., Fairburn CG, Jacoby R., McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry. 1999 ; 174: 39-44. (Pubitemid 29037882)
3. Kawas C., Gray S., Brookmeyer R., Fozard J., Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal study of Aging. Neurology. 2000 ; 54 (11). 2072-2077. (Pubitemid 30397204)
4. Alloul K., Sauriol L., Kennedy W., et al. Alzheimer's disease: a review of the disease, its epidemiology and economic impact. Arch Gerontol Geriatr. 1998 ; 27 (3). 189-221. (Pubitemid 28517904)
5. Rice DP, Fillit HM, Max W., Knopman DS, Lloyd JR, Duttaguptas S. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care. 2001 ; 7 (8). 809-818. (Pubitemid 32815961)
6. Getsios D., Migliaccio-Walle K., Caro JJ NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics. 2007 ; 25 (12). 997-1006. (Pubitemid 350208905)
7. Ballard C., Sorensen S., Sharp S. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. J Alzheimers Dis. 2007 ; 12 (1). 53-59. (Pubitemid 47396304)
8. Wimo A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drugs Aging. 2004 ; 21 (5). 279-295. (Pubitemid 38530455)
9. Green C. Modelling disease progression in Alzheimer's disease: a review of modeling methods used for cost-effectiveness analysis. Pharmacoeconomics. 2007 ; 25 (9). 735-750. (Pubitemid 47481639)
10. Geldmacher DS Cost-effectiveness of drug therapies for Alzheimer's disease: a brief review. Neuropsych Dis Treat. 2008 ; 4 (3). 549-555. (Pubitemid 352037834)
11. Cohen JT, Neumann PJ Decision analytic models for Alzheimer's disease: state of the art and future directions. Alzheimers Dement. 2008 ; 4 (3). 212-222. (Pubitemid 351682261)
12. Neumann PJ Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis. Pharmacoeconomics. 2005 ; 23 (6). 537-541. (Pubitemid 40994123)
13. Stern Y., Albert SM, Sano M., et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994 ; 49 (5). M216 - M222.
14. Trabucchi M. An economic perspective on Alzheimer's disease. J Geriatr Psychiatry Neurol. 1999 ; 12 (1). 29-38. (Pubitemid 29348522)
15. Sano M., Zhu CW, Whitehouse PJ, et al., for the Alzheimer Disease Cooperative Study Group. ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly. Alzheimer Dis Assoc Disord. 2006 ; 20 (4)(suppl3): S191 - S202.
16. Albert SM, Sano M., Bell K., Merchant C., Small S., Stern Y. Hourly care received by people with Alzheimer's disease; results from an urban, community survey. Gerontologist. 1998 ; 38 (6). 704-714. (Pubitemid 29006445)
17. Ernst RL, Hay JW, Fenn C., Tinklenberg J., Yesavage A. Cognitive function and the costs of Alzheimer's disease: an exploratory study. Arch Neurol. 1997 ; 54 (6). 687-693.
18. Fillenbaum G., Heyman A., Peterson BL, Pieper CF, Weiman AL. Use and cost of hospitalization of patients with AD by stage and living arrangement: CERAD XXI. Neurology. 2001 ; 56 (2). 201-206. (Pubitemid 32095361)
19. Fillenbaum G., Heyman A., Peterson BL, Pieper CF, Weiman AL Use and cost of outpatient visits of AD patients: CERAD XXII. Neurology. 2001 ; 56 (12). 1706-1711. (Pubitemid 32574571)
20. Harrow BS, Mahoney DF, Mendelsohn AB, et al. Variation in cost of informal caregiving and formal-service use for people with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004 ; 19 (5). 299-308. (Pubitemid 39382859)
21. Leon J., Neumann PJ The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care. 1999 ; 5 (7). 867-877. (Pubitemid 29356812)
22. Leon J., Cheng CK, Neumann PJ Alzheimer's disease care: costs and potential savings: caring for persons with Alzheimer's disease in the community can save thousands of dollars, but at what cost to family caregivers? Health Aff (Millwood). 1998 ; 17 (6). 206-216.
23. Marin D., Amaya K., Casciano R., et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr. 2003 ; 15 (4). 385-398. (Pubitemid 38186257)
24. Max W., Webber P., Fox P. Alzheimer's disease: the unpaid burden of caring. J Aging Health. 1995 ; 7 (2). 179-199.
25. Murman DL, Chen Q., Powell MC, Kuo SB, Bradley CJ, Colenda CC The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002 ; 59 (11). 1721-1729. (Pubitemid 35424453)
26. Rice DP, Fox PJ, Max W., et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood). 1993 ; 12 (2). 164-176. (Pubitemid 23220072)
27. Small GW, McDonnell DD, Brooks RL, Papadopoulos G. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc. 2002 ; 50 (2). 321-327. (Pubitemid 34132433)
28. Zhu CW, Leibman C., McLaughlin T., et al. The effects of patient function and dependence on costs of care in Alzheimer's disease. J Am Geriatr Soc. 2008 ; 56 (8). 1497-1503.
29. Zhu CW, Leibman C., McLaughlin T., et al. Patient dependence and longitudinal changes in costs of care in Alzheimer's disease. Dement Geriatr Cogn Disord. 2008 ; 26 (5). 416-423.
30. Zhu CW, Torgan R., Scarmeas N., et al. Home health and informal care utilization and costs over time in Alzheimer's disease. Home Health Care Serv Q. 2008 ; 27 (1). 1-20.
31. Zhu CW, Scarmeas N., Torgan R., et al. Clinical features associated with costs in early AD: baseline data from the Predictors study. Neurology. 2006 ; 66 (7). 1021-1028. (Pubitemid 44044785)
32. Zhu CW, Scarmeas N., Torgan R., et al. Longitudinal study of effect of patient characteristics on direct costs in Alzheimer's disease. Neurology. 2006 ; 67 (6). 998-1005. (Pubitemid 44454592)
33. Zhu CW, Scarmeas N., Torgan R., et al. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc. 2006 ; 54 (10). 1596-1602. (Pubitemid 44564156)
34. Zhu CW, Leibman C., Townsend R., et al. Bridging from clinical endpoints to estimates of treatment value for external decision makers. J Nutr Health Aging. 2009 ; 13 (3). 256-259.
35. Knopman DS, Berg JD, Thomas R., Grundman M., Thal LJ, Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology. 1999 ; 52 (4). 714-718. (Pubitemid 29120172)
36. Wattmo C., Wallin AK, Londos E., Minthon L. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist. 2011 ; 51 (1). 17-27.
37. Hatoum HT, Thomas SK, Lin SJ, Lane R., Bullock R. Predicting time to nursing home placement based on activities of daily living scores-a modeling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. J Med Econ. 2009 ; 12 (2). 98-103.
38. Bloom BS, Chhatre S., Jayadevappa R. Cost effects of a specialized care center for people with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004 ; 19 (4). 226-232. (Pubitemid 39095807)
39. Fillit H., Hill J. The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias. Alzheimer Dis Assoc Disord. 2004 ; 18 (suppl 1). S24 - S29.
40. Johnson N., Davis T., Bosanquet N. The epidemic of Alzheimer's disease: how can we manage the costs ? Pharmacoeconomics. 2000 ; 18 (3). 215-223.
41. Murman DL The costs of caring: medical costs of Alzheimer's disease and the managed care environment. J Geriatr Psychiatry Neurol. 2001 ; 14 (4). 168-178. (Pubitemid 33108168)
42. Murman DL, Colenda CC The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden ? Pharmacoeconomics. 2005 ; 23 (3). 227-242. (Pubitemid 40663630)
43. Sano M. Economic effect of cholinesterase inhibitor therapy: implications for managed care. Manag Care Interface. 2004 ; 12 (8). 44-49. (Pubitemid 39202607)
44. Oremus M., Aguilar SC A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011 ; 29 (2). 141-156.
45. Jonsson L., Wimo A. The cost of dementia in Europe: a review of the evidence and methodological considerations. Pharmacoeconomics. 2009 ; 27 (5). 391-403.
46. Mauskopf J., Racketa J., Sherrill E. Alzheimer's disease: the strength of the association of costs with different measures of disease severity. J Nutr Health Aging. 2010 ; 14 (8). 655-663.